已确定的化疗诱导神经病的局部大麻素:试点随机的安慰剂控制试验
Stacy D'Andre1, Paul Novotny2, Camille Walters3
1Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Cannabis and cannabinoid research
|July 17, 2024
概括
这项试点研究发现,局部使用的大麻 (CBD) 奶油并没有显著改善患者的化疗诱导的周围神经病变 (CIPN) 症状. 与安慰剂相比,CBD奶油耐受性很好,没有增加副作用.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 化疗诱导的周围神经病变 (CIPN) 是癌症治疗的常见副作用.
- 患者有事地报告了使用大麻素治疗CIPN的好处.
- 一项试点临床试验旨在研究CBD奶油对CIPN的疗效.
研究的目的:
- 评估局部CBD奶油在改善已建立的CIPN.的有效性.
- 收集数据以支持潜在的III期临床试验.
主要方法:
- 一个双盲,安慰剂控制,随机的试验试验,涉及40名已确立CIPN的患者.
- 患者接受了局部CBD或安慰剂奶油2周,随后进行了2周的交叉治疗.
- 使用EORTC-CIPN20,CIPN评估工具和全球变化印象来评估神经病变;通过症状日记监测副作用.
主要成果:
- 在CBD和安慰剂组之间,EORTC-CIPN20得分没有显著差异.
- 对于CBD和安慰剂治疗,观察到类似的毒性和副作用概况.
- 研究的CBD分离剂奶油没有显示出疼痛确定的CIPN.的改善.
结论:
- 这项试点试验表明,经过测试的CBD隔离乳液对改善已建立的疼痛CIPN无效.
- 发现局部CBD奶油在CIPN.患者中耐受良好.
- 可能需要进一步的研究来探索其他大麻素配方或剂量用于CIPN管理.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
209
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
209
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
158
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
158
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
191
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
191


